




TRANSFORMING WEIGHT LOSS: SEMAGLUTIDE'S MARKET POTENTIAL AND ROLE IN OBESITY MANAGEMENT

PREPARED BY

YASH GOYAL

MBA-PM14

IIHMR-U/02/2022-24/0467

CONTENT

- Obesity
- How to know you are obese?
- Obesity market in global
- What drugs are approved for weight loss?
- Brand and Introduction Semaglutide
- 5C, SWOT, STP, Measurable Goal, Budgeting & 4P's
- Difference between semaglutide and other drugs
- Clinical trials.
- Is weight regaining after stop taking semaglutide?
- Methodology
- Conclusion

OBESITY?

It is the excessive accumulation of fat in the body and the distribution of fat impact metabolic risk.

Body fat display in two types:

Gynecoid or pear-shape



Android or apple-shape



$$\text{BMI} = \frac{\text{Weight in kilogram}}{(\text{Height in meter})^2}$$



HOW TO KNOW YOU ARE OBESE?

Under Weight	Normal weight	Over Weight	Obesity (class I)	Obesity (class II)	Obesity (class III)
					
<18.5	18.5 - 24.5	25 - 29.9	30 - 34.9	35 - 39.9	>40

OBESITY MARKET IN GLOBAL

According to Age wise

Age	Prevalence rate of obesity
0-5	5%
5-9	22%
9-11	15%
11-15	16%
15-18	23%
18-84	24%

According to Prevalence
of child and adult obesity

	Prevalence rate in world
Child	24%
Adult	22%



What drugs are approved for weight loss?

The U.S. Food and Drug Administration (FDA) has approved six medications for weight loss for long-term use:

Drugs	Proprietary Name	Dosage form	Strength	Applicant Holder	Patent No.	Patent Expiration
Bupropion-Naltrexone	Contrave	Tablet, Extended Release; Oral	90mg; 8mg	Nalpropion Pharmaceuticals Llc	7375111	Mar/26/2025
Liraglutide Recombinant	Victoza Saxenda	Solution; Subcutaneous	18mg/3ml (6mg/ML)	Novo Nordisk Inc	7762994	May/23/2024
Orlistat	Xenical	Capsule; Oral	120mg	Cheplapharm Arzneimittel Gmbh	5447953	Jun/14/2013
	Alli		60mg	Haleon Us Holdings Llc		
Phentermine Hydrochloride; Topiramate	Qsymia	Capsule, Extended Release; Oral	Eq 15mg Base;92mg Eq 11.25mg Base;69mg Eq 7.5mg Base;46mg Eq 3.75mg Base;23mg	Vivus Inc	8895058	Jun/09/2028
Semaglutide	Wegovy	Solution; Subcutaneous	0.25mg/0.5ml 0.5mg/0.5ml 1mg/0.5ml 1.7mg/0.75ml 2.4mg/0.75ml	Novo Nordisk Inc	7762994	Mar/2/02026
Setmelanotide Acetate	Imcivree	Solution; Subcutaneous	Eq 10mg Base/ML	Rhythm Pharmaceuticals Inc	9458195	Nov/25/2025

BRANDS OF SEMAGLUTIDE?

Ozempic (injection, prefilled, single-dose pen) for Diabetes.

- 2 mg/1.5 mL (1.34 mg/mL); provides injections of 0.25 mg or 0.5 mg.
- 4 mg/3 mL (1.34 mg/mL); provides 1 mg shot.
- 8 mg/3 mL (2.68 mg/mL); provides 2 mg shot by shot.

Wegovy (Injection, Prefilled, Single-Dose Pen) for Obesity.

0.25mg/0.5ml

0.5mg/0.5ml

1mg/0.5ml

1.7mg/0.75ml

2.4mg/0.75ml

Rybelsus (Oral Tablet) for Obesity.


3mg

7mg

14mg

WHAT IS SEMAGLUTIDE?

- Semaglutide is a GLP-1 antagonist that work by decreases glucagon release, delays stomach emptying, increases insulin release, and decreases appetite.
- Wegovy is only one of the brand of semaglutide which is approved by FDA.
- Dosage form is injection which is prescribes as ones in a week
- Semaglutide injection is in a class of medications called incretin mimetic.



5C ANALYSIS

Company	Highly qualified field force. Convert plan in action. Pan India operation. Active culture.
Competitors	Daily routine exercise. Other FDA approve drug for obesity
Customer	Obese population (Adult) which comes under higher and upper-middle income group.
Collaborator	Logistic transportation company. Doctors, Stockist, Hospitals, Manufacturing company & Stack holder.
Climate	It is approved by FDA. Advance technology to advertise our brand only to doctors. Higher population wants to loss fat. India become a high potential country for semaglutide. Increasing obesity population in India.

SWOT ANALYSIS

Strength

- Well-tolerated side effect profile.
- High effectiveness for weight loss.
- Multifaceted mechanism of action (slow digestion, suppress appetite, and manage blood sugar).
- Synergistic effect on blood sugar control

Weakness

- Injection Requirement
- High Cost

Opportunity

- Growing Obesity Market
- Dosage Flexibility
- Increased Patient Awareness

Threat

- Competition from Existing and New Drugs
- Public Perception and Stigma
- Stringent Regulatory Landscape

STP

Segmentation:-

- Obesity

Target

- Endocrinologists
- Primary Care Physicians (PCPs)
- Bariatric Specialists (specialize in weight loss)

Positioning

We position our brand as obesity remedy

To the Bariatric specialist / Endocrinologists whose goal is to treat obesity and is concerned about the obesity patient those face society discrimination and facing difficulties in doing day to day work. GO-FAT a brand of to treat obesity and provides freedom from obesity and helps to enjoy fat free life.

MEASURABLE GOALS

MRP	6000		Total Population suffering from obesity in india						101470268			
PTR	4285.71											
PTS	3857.14		Total Population suffering from obesity in india (Tire 1 cities)						6,08,82,161			
Target Plan Based on addressing number of Obese Patient												
Cities Tire1	1 Month	2 Month	3 Month	4 Month	5 Month	6 Month	7 Month	8 Month	9 Month	10 Month	11 Month	12 Month
Chennai	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Delhi	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Hyderabad	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Bangalore	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Kolkata	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Mumbai	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Ahmedabad	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Pune	3,55,500	3,91,050	4,30,155	4,73,171	5,20,488	5,72,536	6,29,790	6,92,769	7,62,046	8,38,250	9,22,075	10,14,283
Total to Acchive	28,44,000	31,28,400	34,41,240	37,85,364	41,63,900	45,80,290	50,38,319	55,42,151	60,96,367	67,06,003	73,76,604	81,14,264
6,08,16,903												

Cities Tire2							7 Month	8 Month	9 Month	10 Month	11 Month	12 Month	
Amritsar							263000	289300	318230	350053	385058	423564	
Bhopal							263000	289300	318230	350053	385058	423564	
Bhubaneswar							263000	289300	318230	350053	385058	423564	
Chandigarh							263000	289300	318230	350053	385058	423564	
Faridabad							263000	289300	318230	350053	385058	423564	
Ghaziabad							263000	289300	318230	350053	385058	423564	
Jamshedpur							263000	289300	318230	350053	385058	423564	
Jaipur							263000	289300	318230	350053	385058	423564	
Kochi							263000	289300	318230	350053	385058	423564	
Lucknow							263000	289300	318230	350053	385058	423564	
Nagpur							263000	289300	318230	350053	385058	423564	
Patna							263000	289300	318230	350053	385058	423564	
Raipur							263000	289300	318230	350053	385058	423564	
Surat							263000	289300	318230	350053	385058	423564	
Visakhapatnam							263000	289300	318230	350053	385058	423564	
Agra							263000	289300	318230	350053	385058	423564	
Ajmer							263000	289300	318230	350053	385058	423564	
Kanpur							263000	289300	318230	350053	385058	423564	
Mysuru							263000	289300	318230	350053	385058	423564	
Srinagar							263000	289300	318230	350053	385058	423564	
Total to Acchive							5260000	5786000	6364600	7001060	7701166	8471283	40584109

BUDGETING

Incentive for Dr. on ₹25/patient

Cities Tire1	1 Month	2 Month	3 Month	4 Month	5 Month	6 Month	7 Month	8 Month	9 Month	10 Month	11 Month	12 Month
Chennai	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Delhi	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Hyderabad	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Bangalore	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Kolkata	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Mumbai	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Ahmedabad	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73
Pune	8887500	9776250	10753875	11829262.5	13012188.75	14313407.63	15744748.39	17319223.23	19051145.55	20956260.1	23051886.11	25357074.73

Cities Tire2	1 Month	2 Month	3 Month	4 Month	5 Month	6 Month	7 Month	8 Month	9 Month	10 Month	11 Month	12 Month
Amritsar							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Bhopal							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Bhubaneswar							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Chandigarh							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Faridabad							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Ghaziabad							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Jamshedpur							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Jaipur							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Kochi							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Lucknow							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Nagpur							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Patna							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Raipur							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Surat							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Visakhapatnam							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Agra							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Ajmer							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Kanpur							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Mysuru							6575000	7232500	7955750	8751325	9626457.5	10589103.25
Srinagar							6575000	7232500	7955750	8751325	9626457.5	10589103.25

Cities Tire1	MR	Visual Aid	LBL	Poster	CME	Online marketing
Chennai	1	2000	1440000	144000	120000	10000
Delhi	1	2000	1440000	144000	120000	
Hyderabad	1	2000	1440000	144000	120000	
Bangalore	1	2000	1440000	144000	120000	
Kolkata	1	2000	1440000	144000	120000	
Mumbai	1	2000	1440000	144000	120000	
Ahmedabad	1	2000	1440000	144000	120000	
Pune	1	2000	1440000	144000	120000	
	8	16000	11520000	1152000	960000	10000
Final Expenditure Excl. MR		13658000				

Cities Tire2	MR	Visual Aid	LBL	Poster	CME	Online marketing
Amritsar	1	2000	1440000	144000	120000	20000
Bhopal	1	2000	1440000	144000	120000	
Bhubaneswar	1	2000	1440000	144000	120000	
Chandigarh	1	2000	1440000	144000	120000	
Faridabad	1	2000	1440000	144000	120000	
Ghaziabad	1	2000	1440000	144000	120000	
Jamshedpur	1	2000	1440000	144000	120000	
Jaipur	1	2000	1440000	144000	120000	
Kochi	1	2000	1440000	144000	120000	
Lucknow	1	2000	1440000	144000	120000	
Nagpur	1	2000	1440000	144000	120000	
Patna	1	2000	1440000	144000	120000	
Raipur	1	2000	1440000	144000	120000	
Surat	1	2000	1440000	144000	120000	
Visakhapatnam	1	2000	1440000	144000	120000	
Agra	1	2000	1440000	144000	120000	
Ajmer	1	2000	1440000	144000	120000	
Kanpur	1	2000	1440000	144000	120000	
Mysuru	1	2000	1440000	144000	120000	
Srinagar	1	2000	1440000	144000	120000	
	20	40000	28800000	2880000	2400000	20000
Final Expenditure Excl. MR		34140000				

4 P'S

Product	GO-FAT (Semaglutide) inj. Free exercise guidance. Emboss brand name with UV. Pack of 4 one-month therapy.
----------------	--


Price	MRP = 6000 PTR = 4285.71 PTS = 3857.14 Competitor Pricing = ₹7000/- to ₹7800/- 15 days credit to stockist
--------------	--

Place	Presence on both online and offline Pan-India First inventory = 11376000/- By temperature control truck with distribution partners
--------------	---

Promotion	Creating awareness about diabetes. Creating buzz that only exercise and diet are not effective for weight loss. Promotion by Omni-channel. CME. Those buy 6-month therapy they got 20% discount for consumer.
------------------	--

MOA OF SEMAGLUTIDE

Position 26 lysine is modified with a C18 fatty di-acid and a hydrophilic spacer to facilitate albumin binding, the main mechanism of semaglutide's protraction. Furthermore, semaglutide's position 8 modification offers stability against the enzyme DPP-4 degradation. To ensure that there was only one fatty di-acid attached, position 34 was slightly changed.



DIFFERENCE BETWEEN SEMAGLUTIDE AND OTHER DRUGS

Drug (Brand Name)	Mechanism of Action	Dosage Form	How it Works	Potential Advantages
Semaglutide (Wegovy, Ozempic)	An agonist of the GLP-1 (glucagon-like peptide-1) receptor	Injection (weekly or daily)	Slows stomach emptying, raises satiety, decreases glucagon secretion, and increases insulin secretion.	Among these drugs, the one with the highest average weight reduction can help regulate blood sugar.
Bupropion-naltrexone (Contrave)	Bupropion, an inhibitor of dopamine and norepinephrine reuptake, combined with naltrexone, an opioid receptor antagonist.	Tablet	May improve sensations of fullness and reduce cravings.	Has the ability to lessen alcohol cravings and may be more tolerable than stimulants.
Liraglutide (Saxenda)	An agonist of the GLP-1 (glucagon-like peptide-1) receptor	Injection (daily)	slows stomach emptying, raises satiety, decreases glucagon secretion, and increases insulin secretion	Like semaglutide, but possibly less effective in reducing body weight
Orlistat (Xenical, Alli)	Lipase inhibitor	Capsule	prevents some dietary fat from being absorbed	Possibly a decent choice for those who have trouble eating meals high in fat.
Phentermine-topiramate (Qsymia)	Stimulant (phentermine) + anticonvulsant (topiramate)	Capsule	suppresses hunger and could speed up metabolism	perhaps beneficial for temporary weight loss
Setmelanotide (Imcivree)	Melanocortin-4 receptor (MC4R) agonist	Injection (monthly)	stimulates brain receptors that control hunger and energy expenditure	For those with genetic abnormalities impacting appetite regulation, it might be a possibility.

SWOT ANALYSIS OF SEMAGLUTIDE INJECTION

Strength

- **Well-tolerated side effect profile.**
- **High effectiveness for weight loss.**
- **Multifaceted mechanism of action (slow digestion, suppress appetite, and manage blood sugar).**
- **Synergistic effect on blood sugar control**

Weakness

- **Injection Requirement**
- **High Cost**

Opportunity

- **Growing Obesity Market**
- **Dosage Flexibility**
- **Increased Patient Awareness**


Threat

- **Competition from Existing and New Drugs**
- **Public Perception and Stigma**
- **Stringent Regulatory Landscape**

CLINICAL STUDIES

CT-1-ADULTS WITH OBESITY OR OVERWEIGHT AND CARDIOVASCULAR DISEASE: CARDIOVASCULAR OUTCOMES TRIAL

In this study, 17,604 participants were randomized at random to receive semaglutide or a placebo. 84% White, 4% Black or African American, 8% Asian, and 10% Hispanic or Latino made up the baseline demographics, which included 72% of men. The age range was 45-93 years, with a mean of 62. The mean body weight was 97 kg, and the average baseline BMI was 33 kg/m².



	Placebo		Semaglutide		
	Baseline	Change from Baseline (LSMean)	Baseline	Change from Baseline (LSMean)	Difference from Placebo (LSMean)
Body Weight (kg)	96.8	-0.9	96.5	-9.4	-8.5
Waist Circumference (cm)	111.4	-1.0	111.3	-7.6	-6.5
Systolic Blood Pressure (mmHg)	131	-0.5	131	-3.8	-3.3
Diastolic Blood Pressure (mmHg)	79	-0.5	79	-1.0	-0.5
Heart Rate	69	0.7	69	3.8	3.1
HbA1c (%)	5.8	0.0	5.8	-0.3	-0.3
	Baseline	% Change from Baseline (LSMean)	Baseline	% Change from Baseline (LSMean)	Relative difference from placebo (%) (LSMean)
Total Cholesterol (mg/dL)	156.0	-1.9	155.5	-4.6	-2.8
LDL Cholesterol (mg/dL)	78.5	-3.1	78.5	-5.3	-2.2
HDL Cholesterol (mg/dL)	44.2	0.6	44.1	4.9	4.2
Triglycerides (mg/dL)	139.5	-3.2	138.6	-18.3	-15.6

CT-2: STUDIES ON WEIGHT LOSS AND LONG-TERM MAINTENANCE IN OBESE OR OVERWEIGHT ADULTS

Changes in Body Weight at Week 68 in Studies 2, 3, and 4

	Study 2 (Obesity or overweight with comorbidity)		Study 3 (Type 2 diabetes with obesity or overweight)		Study 4 (Obesity or overweight With comorbidity undergoing intensive lifestyle therapy)	
Intention-to-Treat	Placebo N=655	Semaglutide N=1306	Placebo N=403	Semaglutide N=404	Placebo N=204	Semaglutide N=407
Body Weight						
Baseline mean (kg)	105.2	105.4	100.5	99.9	103.7	106.9
% change from Baseline (LSMean)	-2.4	-14.9	-3.4	-9.6	-5.7	-16.0
% difference from placebo (LSMean) (95% CI)		-12.4 (-13.3; -11.6)*		-6.2 (-7.3; -5.2)*		-10.3 (-11.8; -8.7)*
% of Patients losing greater than or equal to 5% body weight	31.1	83.5	30.2	67.4	47.8	84.8
% difference from placebo (LSMean) (95% CI)		52.4 (48.1; 56.7)*		37.2 (30.7; 43.8)*		37.2 (30.7; 43.8)*
% of Patients losing greater than or equal to 10% body weight	12.0	66.1	10.2	44.5	27.1	73.0
% difference from placebo (LSMean) (95% CI)		54.1 (50.4; 57.9)*		34.3 (28.4; 40.2)*		45.9 (38.0; 53.7)*
% of Patients losing greater than or equal to 15% body weight	4.8	47.9	4.3	25.1	13.2	53.4
% difference from placebo (LSMean) (95% CI)		43.1 (39.8; 46.3)*		20.7 (15.7; 25.8)*		40.2 (33.1; 47.3)*

To investigate the safety and efficacy of Semaglutide for weight loss and long-term maintenance of body weight in conjunction with a reduced calorie diet and increased physical activity, three 68-week randomized, double-blind, placebo-controlled trials, one 68-week randomized, double-blind, placebo withdrawal trial, and a second 68-week randomized, double-blind trial comparing two different doses of Semaglutide to placebo were carried out.

Changes in Body Weight at Week 68 in Study 5 (Obesity or overweight with comorbidity after 20-week run-in)

	Semaglutide N=803	
Body Weight (only randomized patients)		
Mean at week 0 (kg)	107.2	
	Placebo N=268	Semaglutide N=535
Body Weight		
Mean at week 20 (SD) (kg)	95.4 (22.7)	96.5 (22.5)
% change from week 20 at week 68 (LSMean)	6.9	-7.9
% difference from placebo (LSMean) (95% CI)		-14.8 (-16.0; -13.5) *

Changes in Body Weight at Week 68 in Study 6 in East-Asian Patients (Semaglutide 1.7 mg)

	Study 6 (BMI ≥35 kg/m ² with at least one comorbidity or BMI 27-34.9 kg/m ² with at least two comorbidities)		
Intention-to-treat	Placebo N=101	Semaglutide 1.7 mg N=101	Semaglutide 2.4 mg N=199
Body Weight			
Baseline mean (kg)	90.2	86.1	86.9
% change from baseline (LSMean)	-2.1	-9.6	-13.2
% difference from placebo (LSMean) (95% CI)		-7.5 (-9.6; -5.4)*	-11.1 (-12.9; -9.2)*
% of patients losing greater than or equal to 5% body weight	19.4	72.8	84.0
% difference from placebo (LSMean) (95% CI)		53.3 (41.0; 65.6)*	64.5 (54.8; 74.3)*
% of patients losing greater than or equal to 10% body weight	4.5	39.1	59.9
% difference from placebo (LSMean) (95% CI)		34.5 (23.9; 45.1)*	55.4 (47.3; 63.6)*
% of patients losing greater than or equal to 15% body weight	2.6	20.8	38.2
% difference from placebo (LSMean) (95% CI)		18.2 (9.8; 26.7)*	35.6 (27.9; 43.3)*

CT-3- WEIGHT LOSS AND LONG-TERM MAINTENANCE RESEARCH IN PEDIATRIC OBESITY PATIENTS 12 YEARS OF AGE AND UP

201 Pediatric patients in their pubertal years, aged 12 and older, whose BMI fell within the ≥ 95 th percentile normalized for age and sex, participated in a multi-centre, 68-week, double-blind, randomized, parallel group, placebo-controlled study.

The patients' racial or ethnic backgrounds were as follows: 79% were White, 8% were Black or African American, 2% were Asian, and 11% were of other or unknown race. The patients' average age was fifteen years, and 38% of them were male. The average baseline body weight was 108 kg, and the mean BMI was 37 kg/m².

Result

Ten percent of patients receiving WEGOVY® treatment and ten percent of patients receiving a placebo quit taking the study drug.

The primary result was the percentage change in BMI from baseline to week 68. After 68 weeks, WEGOVY® treatment resulted in a statistically significant reduction in percentage BMI when compared to a placebo. A greater proportion of patients treated with WEGOVY® saw a $\geq 5\%$ reduction in their initial BMI compared to patients treated with placebo.

Changes in Weight and BMI at Week 68 in Pediatric Patients with Obesity Aged 12 Years and Older


Intention-to-Treat	Placebo N=67	Wegovy N=134
BMI		
Baseline mean (kg/m)	35.7	37.7
% change from baseline in BMI (LSMean)	0.6	-16.1
% difference from placebo (LSMean) (95% CI)		-16.7 (-20.3; -13.2)
% of patients with greater than or equal to 5% reduction in baseline BMI	19.7	77.1
% difference from placebo (LSMean)		57.4
% of patients with greater than or equal to 10% reduction in baseline BMI	7.7	65.1
% difference from placebo (LSMean)		57.5
% of patients with greater than or equal to 15% reduction in baseline BMI	4	57.8
% difference from placebo (LSMean)		53.9
Body Weight		
Baseline mean (kg)	102.6	109.9
% change from baseline (LSMean)	2.7	-14.7
% difference from placebo (LSMean)		-17.4

WEIGHT REGAINS AND CARDIOMETABOLIC EFFECTS AFTER WITHDRAWAL OF SEMAGLUTIDE?

Yes, it can be.

Extension analyses included 327 participants. From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120. Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.

One year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss, with similar changes in cardiometabolic variables. Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.



METHODOLOGY

Research Question:

- To know about various US FDA, approve medication for obesity.
- To find solutions to obesity patients.
- To know about limitations of semaglutide.
- To know about the effectiveness of semaglutide.

Research Objective:

- In-depth learning of Obesity.
- To learn about treatments for obesity.
- Semaglutide as an effective drug in treatment of obesity.
- Efficacy & Safety of semaglutide in obesity patients.
- Wegovy Trial

Study Area: Field knowledge about obesity and potency of Semaglutide.

Study Design: Observational study.

Study Tool: Review articles, Research articles, field understanding.

Study Duration: 90 days

CONCLUSION

- Semaglutide is best and most effective drug for treating obesity. Semaglutide show higher reduction in weight than other drugs. Semaglutide also have lower does frequency and have less side-affect than other drug.
- Semaglutide is best for obesity patient those are suffer from diabetes because it has a synergistic effect in controlling hyperglycaemia.



Thank
you!